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ABSTRACT 
BACKGROUND 
Glomerulonephritis is a common cause of end-stage renal disease (ESRD) in developing 
countries. Idiopathic membranous nephropathy (IMGN) is an identified cause of nephrotic 
syndrome in South Africa.  Early attainment of complete remission (CR) or partial remission 
(PR) in patients with IMGN has been shown to slow progression to ESRD. There is a dearth 
of outcome studies in Africa on IMGN. 
METHODS 
This study was approved by the institution’s Human Research Ethics Committee. It was a 
retrospective review of patients diagnosed (biopsy-proven) with IMGN at the Division of 
Nephrology and Hypertension, Groote Schuur Hospital, Cape Town, over a 10 year period. 
Secondary causes of MN were excluded in this study. Demographic, clinical, biochemical and 
histological records of such patients were retrieved for analysis. The trends in clinical and 
biochemical parameters over the course of follow-up from baseline were also determined. 
The primary outcome of interest was the attainment of a CR or PR at the last date of follow-
up. Predictors of the composite of CR and PR at the last follow-up visit were assessed using 
univariate and multivariate Cox-Regression analysis. The trend in estimated glomerular 
filtration rate over the median duration of follow-up was evaluated as a secondary 
outcome. 
RESULTS 
There were 56 patients with histologic and clinical parameters compatible with the 
diagnosis of IMGN. There were 26/56 females (46.4%) with an overall mean age of 
41.5±14.6 years.  Forty-three (43) patients had subsequent follow-up care at our centre with 
a median duration of follow-up of 23.0 (13.0, 48.0) months. Sixteen patients (37.2%) were 
treated with immunosuppression (ISP) -combination of steroids and cyclophosphamide, and 
81.4% received renin-angiotensin system (RAS) blockade. There were no statistically 
significant differences in demographic and clinical features of patients treated with or 
without ISP. Trends in level of proteinuria, estimated GFR and serum albumin 
concentrations were also not significantly different between the 2 groups. Eighteen patients 
(41.9%) reached CR or PR at the last visit. There were also no statistically significant 
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differences in demographic, clinical, histological, and biochemical characteristics of patients 
who had or had not achieved remission. The median time-to-remission of patients treated 
with or without ISP was similar - 48.6 and 48.7 months respectively (p=0.13) while the 
proportions of patients not reaching CR/PR at 1 year and 2 years were 94.6% and 80.8% 
respectively by Kaplan-Meier analysis. Gender, race and use of immunosuppression did not 
influence remission status (log rank p>0.05). On regression analysis, the predictors of CR/PR 
at last follow up visit were GFR [OR 1.01 (95%CI: 1.00 – 1.02); p=0.041] and systolic BP (OR 
0.97 [95%CI: 0.95 – 0.99); p=0.036].  
CONCLUSION 
Remission outcomes with the current immunosuppressive treatment protocol for IMGN are 
delayed and poor. There is a need for its re-evaluation and also for longitudinal, multicenter 

















































End stage renal disease continues to impose an increased burden on scarce health resources in sub-
Sahara Africa (SSA) where there is a transition in epidemiology from the predominance of 
communicable diseases to the co-dominance of communicable and non-communicable diseases.1,2 
While diabetes mellitus is the leading cause of end-stage renal disease (ESRD) in industrialized 
societies, glomerulonephritis (GN) and systemic hypertension are the more prevalent causes of ESRD 
in SSA.1  
GN may present clinically as a nephritic or a nephrotic syndrome. The spectrum of GN disorders 
associated with the nephrotic syndrome varies between children and adults with idiopathic 
membranous glomerulonephritis (IMGN) reported to be the commonest and second commonest 
cause of nephrotic syndrome in adults in Europe and the United States respectively.3 Membranous 
GN has been reported to account for 11.6% of cases with nephrotic range proteinuria in South 
Africa.4  
Membranous GN may occur as an idiopathic disease or may be secondary to the presence of other 
conditions such as infections, autoimmune diseases, malignancies and drugs.5 The distinction 
between idiopathic and secondary MGN rests on the absence of an identifiable systemic cause after 
an exhaustive and systematic search. Systemic conditions associated with MGN include chronic viral 
infections such as Hepatitis B and C, systemic autoimmune disorders such as systemic lupus 
erythematosus (SLE), rheumatoid arthritis, IgG4-related systemic disease, syphilis, and malignancies 
such as non-Hodgkin lymphoma, lung, colon, and breast tumours.5 Drugs such as gold, D-
penicillamine, non-steroidal anti-inflammatory agents and mercury-containing compounds are also 
known secondary causes of MGN.5 
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Idiopathic membranous GN (IMGN) is second only to focal segmental glomerulosclerosis (FSGS) as a 
cause of primary nephrotic syndrome globally in all adults; it is however the commonest cause of 
primary nephrotic syndrome among Caucasian adults.6,7 While the exact pathogenic mechanisms 
involved in idiopathic MGN are not completely defined, an autoimmune basis has been established 
with a number of target human glomerular antigens identified. These include neutral 
endopeptidase, M-type phospholipase A2 receptor 1(M-PLA2R1), and thrombospondin type I 
domain-containing 7A (THSD7A).8,9 This glomerular disease is characterized by the presence of 
diffuse and global glomerular sub-epithelial deposits on microscopy- a rather unique characteristic 
which makes the diagnosis of MGN possible with only one glomerulus on microscopy.6  Minimal to 
absent cellular proliferation and the predominance of IgG4 on immunofluorescence distinguish 
IMGN from secondary MGN.6  
IMGN is the most common cause of nephrotic syndrome in all adults worldwide with a reported 
incidence rate of 1.2 /100,000/year.10,11  Incidence rates have remained unchanged in almost half a 
decade.11 IMGN is more common among males with a male to female distribution of 2:1.12 It is a 
disease of adults with a peak incidence between the 3rd and 5th decades of life; IMGN rarely occurs in 
children.5,13 It has no racial predilection with similar incidence rates among all racial groups. This is in 
contrast to what has been described in other primary glomerulonephritides such as 
primary/idiopathic focal segmental glomerulosclerosis (FSGS) in which there is a higher incidence 
among blacks, or IgA glomerulonephritis with a higher incidence among Asians.14  However, 
variability in the regional incidence rates of IMGN has been noted and it is uncertain if this truly 
reflects regional disease distribution.  Current regional differences in reported incidence rates are 
believed to reflect differences in access to diagnostic renal biopsy services with subsequent under-
reporting of cases from disadvantaged regions.11 IMGN can also occur in the renal allograft where it 
may occur either as a recurrent disease or a de novo disease.6  
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The natural history of  IMGN has been classically described by the “rule of thirds” in which a third of 
patients enter into  partial or complete remission, a third continue to have nephrotic-range 
proteinuria with a normal or impaired (but stable) renal function and a third progress to ESRD.6 
Young age, female gender, low-grade proteinuria, partial or complete remission, and Asian ancestry 
have been identified as favourable prognostic factors in IMGN.15-17 The various management 
strategies for IMGN have thus been oriented towards maximizing the number of patients who go 
into some form of remission, and improving aspects of the natural history of the disease associated 
with poor patient outcome. These include retarding progression to ESRD and reducing the 
proportion of patients with continued proteinuria and its attendant complications.18 
Reduction in proteinuria is known to retard the decline of renal function in non-diabetic proteinuric 
diseases.19 Similarly, the occurrence of remission in IMGN patients is associated with improved renal 
survival.20 These observations have thus placed premium on the value of remission of proteinuria as 
both a treatment target and an outcome measure in IMGN. While earlier studies of IMGN had 
demonstrated favourable renal and patient survival with the attainment of a complete remission of 
proteinuria, Troyanov et al have additionally demonstrated that attaining a partial remission of 
proteinuria in IMGN is associated with favourable long-term renal outcomes.21 Partial remission is 
thus as compelling a management target as spontaneous remission in IMGN.  Remission in IMGN 
may occur spontaneously or may be induced by the use of immunosuppressive therapy. It is known 
that spontaneous remissions occur the most in IMGN of all proteinuric glomerular disorders.10 
Spontaneous remissions are however less likely with increasing severity of proteinuria. Among a 
Spanish cohort of IMGN patients, the proportion of spontaneous remitters (complete or partial) 
declined from 37.1% to 21.5% as baseline proteinuria increased from a daily maximum of 
8g/24hours to >12g/24hours.22 The landmark immunosuppressive trial in IMGN patients by Ponticelli 
utilizing the alkylating agent Chlorambucil in combination with corticosteroids proved that remission 
rates can be increased to almost 90% among IMGN patients actively treated with 
immunosuppressive agents.23  
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The stabilization of renal function, and by extension the retardation of progression to ESRD, has 
been described as one of the ultimate goals of management in IMGN.10 Renal survival during follow-
up is hence a frequently observed outcome measure in studies among IMGN patients. Risk 
assessment and subsequent categorization into low, medium and high risk in IMGN is based on the 
likelihood of progression to ESRD.15,24 Patients’ risk of progression is determined by the composite of 
renal function and proteinuria at baseline.  Beyond its use in grouping patients according to 
progression potential, risk categorization has also been used as a tool to guide the need for initiation 
of active (immunosuppressive) treatment in IMGN.10 The role immunosuppressive therapy plays in 
stabilizing renal function decline and retardation of progression to ESRD has been variously 
established. ESRD-free survival rate was 92% after 10 years of follow-up among patients who had 
been actively treated with immunosuppression versus 60% who received only supportive care in the 
trial of alkylating agents in IMGN.23  Similar trends in renal survival have also been shown when 
active treatment is targeted towards patients with an ab initio high risk of ESRD progression.25 
The goals of treatment in IMGN include the preservation of renal function and prevention of the 
complications of the nephrotic syndrome.18 Current guidelines recommend treatment for IMGN 
patients with nephrotic syndrome and any of urinary protein >4g/day, disabling or life-threatening 
symptoms of nephrotic syndrome or a rise in serum creatinine >30% over 6-12 months with an 
estimated glomerular filtration rate of ≥ 25-30mls/min/1.73m2.14 Available therapeutic agents 
include oral and intravenous corticosteroids, alkylating agents such as Cyclophosphamide and 
Chlorambucil, the calcineurin inhibitors (CNI) e.g. cyclosporine, tacrolimus, and biological agents 
such as Rituximab. 
The various ISP agents available for the treatment of IMGN are combined into various regimens that 
are available for use in current clinical practice. While there are no head-to-head trials comparing 
the superiority or non-inferiority of the various regimens, a recent systematic review showed that 
the combination regimen of an alkylating agent with corticosteroid was significantly associated with 
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higher complete and partial remission rates, a reduction in all-cause mortality and ESRD. These 
benefits however come at the expense of an increased risk of therapy discontinuation and 
hospitalizations due to adverse events.26 
Renal transplantation is a treatment option in iMGN patients who have progressed to ESRD. The 
disease may however emerge in the transplanted kidney either as a de novo disease (approximately 
70% of cases) or as a recurrence of the primary glomerular disease.6 Recurrence in the renal allograft 
may be as high as 42% and account for 12.5% of graft losses at 10 years.27,28   
RATIONALE OF THE RESEARCH 
If the tide of ESRD from GN is to be stemmed in Africa, it is imperative that clinical outcome data, in 
addition to epidemiologic data, be made available to influence appropriate health policy formulation 
and implementation.  Some data is available in Africa describing the frequency of occurrence of 
IMGN as a cause of primary glomerulonephritis and nephrotic syndrome.4,29  There is however a 
dearth of data in the literature describing the clinical characteristics and course of IMGN in South 
Africa, and indeed Africa as a whole. In addition, data is scarce on the outcomes of remission, renal 
survival, and patient survival in IMGN. The clinical outcomes of patients with secondary 
membranous GN from lupus nephritis from our centre has been previously described.30  
We therefore sought to describe the clinical outcomes of IMGN among South African adults 
attending the Division of Nephrology and Hypertension of Groote Schuur Hospital over the 10-year 
period 1st January, 2003 to 31st December, 2013. Our specific objectives were: 
1. To describe pattern of idiopathic membranous glomerulonephritis in our patient population of
Africans, 
2. To describe the clinical outcomes of patients with idiopathic membranous glomerulonephritis in
our setting, and 
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3. To determine the association between baseline clinical characteristics and clinical outcomes in our 
cohort of idiopathic membranous glomerulonephritis patients. 
 
RESEARCH SETTING 
This study was carried out at the Division of Nephrology and Hypertension, Groote Schuur Hospital 
(GSH), Cape Town. GSH is one of two provincial government-funded, adult, academic tertiary health 
facilities that serve the central health district of the Cape Town Metro region.31 The catchment 
population of the facility encompasses a diverse socioeconomic and cultural group.  The study was a 
10-year retrospective review of biopsy-proven IMGN in adults that had been diagnosed and 
managed within the Division of Nephrology and Hypertension at GSH.  All adult IMGN patients from 
the period 1st January, 2003 to 31st December, 2013 were identified from the division’s renal biopsy 
register. 
1.2 ETHICAL CONSIDERATIONS 
The ethical issues taken into consideration in this study relate to gaining access to protected 
patients’ information contained within medical records, and the maintenance of confidentiality of 
such information obtained for the conduct of this study. Ethical approval was thus obtained from the 
Human Ethics Research Committee, University of Cape Town (HREC/REF: 046/2014).  
 
1.3 AUTHOR GUIDELINES FOR THE NEPHROLOGY DIALYSIS TRANSPLANTATION 
JOURNAL 
Author guidelines for article submission to the Nephrology Dialysis Transplantation Journal of the 
European Renal Association-European Dialysis and Transplantation Association [ERA-EDTA] (in their 
exact words) are attached in appendix 1. 
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ABSTRACT 
Background: Idiopathic membranous glomerulonephritis (IMGN) is an identified cause of 
nephrotic syndrome in South African adults.  Remission outcomes in affected patients remain 
unknown.  
Methods: This was a retrospective review of patients with biopsy-proven IMGN over a 10 
year period. Secondary causes of MN were excluded. Demographic, clinical, biochemical and 
histological records were retrieved for analysis. The trends in biochemical parameters from 
baseline were determined. The primary outcome was the attainment of a complete or partial 
remission (CR / PR) at the last follow-up.  
Results: Fifty-six patients met the criteria for inclusion and 43 had subsequent follow-up care 
with a median duration of follow-up of 23.0 (13.0 - 48.0) months. Sixteen patients (37.2%) 
were treated with immunosuppression (corticosteroids and cyclophosphamide) and 81.4% 
received anti-proteinuric agents. There were no significant differences in demographic and 
clinical features of patients categorized by immunosuppression (ISP) use. Changes in level of 
proteinuria and estimated glomerular filtration rate (eGFR) were also not significantly 
different between the 2 groups. Eighteen patients (41.9%) reached CR or PR at the last visit. 
The median times-to-remission of patients according to ISP status were similar  at 48.6 and 
48.7 months respectively (p=0.104) while the proportions of patients not reaching CR/PR at 
12 and 24 months were 94.6% and 80.8% respectively. Gender and race did not predict 
remission status (p>0.05). Predictors of CR/PR at last visit were eGFR [OR 1.01 (95%CI: 
1.00 – 1.02); p=0.041], and systolic BP (OR 0.97 [95%CI: 0.95 – 0.99); p=0.036].  
Conclusion: Remission outcomes in this African IMGN cohort are delayed and poor.  
(248 words) 
Keywords: Idiopathic Membranous glomerulonephritis, Remission, South Africa,  
 
SHORT SUMMARY 
Patient outcomes among Africans with idiopathic membranous glomerulonephritis is 
unknown. Remission outcomes in South Africans with the current immunosuppressive 
regimen is delayed and poor. There is the need to review the current treatment approaches to 
IMGN in Cape Town. 
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INTRODUCTION 
Glomerulonephritis remains a prevalent cause of end-stage renal disease (ESRD) in Sub-
Saharan Africa (SSA).1  Idiopathic membranous glomerulonephritis (IMGN) is the 
commonest cause of primary nephrotic syndrome (NS) in adults and ranks as the third 
commonest cause of nephrotic range proteinuria in South African adult population.2,3 It is 
considered to be a renal-limited autoimmune disorder in which autoantibodies are formed 
against one or more constituent podocyte autoantigens.4 Two such autoantigens have been 
identified to date and include the phospholipase A2 receptor and the thrombospondin type-1 
domain containing 7A.4,5 The specific pathogenetic mechanism that triggers autoantibody 
production remains unknown.  
The natural history of outcomes in IMN has historically been described by the rule of thirds 
whereby a third of patients attain spontaneous remission, a third remain proteinuric, and a 
third progress inexorably to renal failure.6 Clinical outcome studies have thus been oriented 
towards evaluating the modification of the natural history of IMGN with the use of 
immunosuppressive (ISP) medications, and also determining the best ISP regimen to achieve 
this. Study findings have not been consistent in supporting an obligatory role for ISP 
treatment. It has been demonstrated that approximately 50% of untreated patients will 
develop spontaneous or partial remission of proteinuria - a phenomenon that has also been 
demonstrated among untreated IMGN patients with renal impairment at diagnosis.7,8  
The debate on the need for immunosuppressive treatment in IMGN has centered on the role 
such treatment plays in altering patient outcomes and determining the appropriate candidate 
in whom remission would otherwise not be achieved without the use of 
immunosuppression.9,10 Remission attainment and renal survival are the best and accepted 
outcome measures in IMGN.2 Outcome studies in the era of immunosuppression addressing 
these endpoints have shown benefit in nephrotic IMGN patients with and without renal 
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impairment at the initiation of therapy.11,12 There is a paucity of outcome data in adults with 
IMGN in SSA and we therefore sought to describe the clinical characteristics and remission 
outcomes in patients with biopsy-proven IMGN at our centre. The primary outcome of 
interest was the composite of complete and partial remission with respect to 
immunosuppression use.  The change in estimated glomerular filtration (eGFR) rate over 
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SUBJECTS AND METHODS 
The study was approved by the Human Research Ethics Committee of the University of Cape 
Town (HREC/REF: 046/2014). 
Patients 
Patients with IMGN were identified from the renal biopsy registry of the Division of 
Nephrology and Hypertension (DNH), Groote Schuur Hospital (GSH), University of Cape 
Town. The case records of all biopsy-proven IMGN patients who were treated and followed 
up between 1st January, 2003 and 31st December, 2013 at the DNH were subsequently 
retrospectively assessed. Probable secondary causes of Membranous GN were thoroughly 
sought from serologic work-up for systemic lupus erythematosus, testing for chronic 
infections such as chronic hepatitis B infection, syphilis, and a work-up for malignancy. 
Individuals with documented positive tests were excluded.  
 
Data collection 
Demographic, biochemical and clinical data were collected at the time of the diagnostic renal 
biopsy and at subsequent visits until the last visit within the study duration, or occurrence of 
death. Demographic data collected include age, gender and race while clinical and 
biochemical data collected at each of these time points include systolic blood pressure (SBP), 
diastolic blood pressure (DBP), serum creatinine, eGFR using the MDRD 4-variable 
equation, and 24-hour urinary protein excretion by a spot urine protein-creatinine ratio 
determination. Anti-phospholipase A2 receptor 1 (PLA2R1) antibodies assessment was not 
done due to unavailability of stored sera.  
All immunosuppressive therapies administered were documented. All patients who received 
immunosuppression got initial therapy according to the unit protocol [1g Methylprednisone 
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followed by Prednisone 40mg daily for one month alternating with monthly intravenous (IV) 
cyclophosphamide 750mg/m2 body surface area (BSA) for 6 months with steroid taper to 
10mg at 6 months]. Probable complications from all medications given and known 
complications of IMGN, other than renal insufficiency, were also reviewed.  
Definitions 
 Glomerular filtration rate was estimated using the 4-variable modification of diet in
renal disease (MDRD) equation.13
 A complete remission was defined as proteinuria ≤ 300mg/day and a partial remission
defined as proteinuria <3.5g/day with a reduction from its peak value by 50%.14
Remission status was allocated if either partial or complete remission criteria were
met and if eGFR was > 15mls/min.14
 Nephrotic syndrome at presentation was defined as proteinuria ≥ 3.5g/day with serum
albumin < 30g/L.
 Time to remission was determined from the time of the diagnostic kidney biopsy.
Use of immunosuppressive agents was reported as intent-to-treat irrespective of duration of 
therapy.14 Patients were categorized into two groups based on treatment with 
immunosuppression. Actual immunosuppressive therapy received consisted of at least 30mg 
of prednisone with or without Methylprednisone monthly alternating with 750mg/m2 BSA of 
IV cyclophosphamide; no patient had monotherapy.  The use of warfarin, RAAS blockade 
and antihypertensives was categorized by exposure status. 
Histology 
The diagnosis of IMGN was made based on typical light microscopy findings of spikes on 
silver-methenamine stain, immunocytochemistry findings of IgG and C3 in the peripheral 
capillary loops, and electron microscopy (EM) findings of sub-epithelial deposits. Histologic 
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staging of glomerular basement membrane thickening into stages I-IV was done according to 
the criteria by Ehrenreich et al, while interstitial fibrosis (IF) was graded as absent, mild, 
moderate or severe.15  
Statistical analysis 
Data analysis was performed using Stata® 13 software (Stata Corp, Texas). Continuous 
variables were expressed as mean ± standard deviation for normally distributed variables and 
median (interquartile range [IQR]) for non-parametric continuous variables; comparisons 
were made using an independent sample student’s t-test or a Wilcoxon rank-sum test where 
appropriate. Categorical variables were presented as frequencies and percentages with 
comparisons made using a Chi-square test or Fisher’s exact test where appropriate. Analyses 
of response profiles were utilized to assess the trend of proteinuria and eGFR over time and 
the predictors of observed trends.  
Time-to-remission analysis was done using Kaplan-Meier survival analysis. Time-to-
remission estimates were compared between groups by log-rank test after censoring for loss-
to-follow up. Multivariate Cox proportional hazards regression analysis (utilizing selected 
covariates from univariate analysis) was used to determine possible predictors of remission. 
A p-value of <0.05 was considered statistically significant. 
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RESULTS 
Demographic, clinical and biochemical features at baseline 
Ninety-two patients had a histologic diagnosis of membranous glomerulonephritis. Thirty-six 
patients with identified secondary causes of membranous GN were excluded (Figure 1).  As 
shown in Table 1 among the 56 patients identified as IMGN at biopsy, 43 (77.0%) had 
nephrotic syndrome at presentation. Mean age at presentation was 41.5 ±14.6 years, 46.4% 
were females and 37.5% were blacks. Median serum creatinine at presentation was 79.5 (IQR 
61.5, 118.0) µmol/L, with a median eGFR of 88.4 (IQR 60.0-134.8) mls/min/1.73m2.  
Median UPCR was 0.98 (IQR 0.66, 1.37) g/mmol with a mean serum albumin of 19.1 ±7.0 
g/L for the entire group. The average number of glomeruli obtained at biopsy was 12.7 ± 7.8 
with the most frequently occurring EM stage of IMGN being stage 2 (34.9%) The highest 
number of sclerosed glomeruli in a single biopsy was 8 (min, max 0, 8) and IF was 
demonstrable in 43.1% of biopsies (Table 2).  
Baseline characteristics of patients followed up at the DNH-GSH  
Thirteen (13) patients who were followed up at other health facilities were excluded from 
further analysis. Forty-three (43) patients were followed up at DNH-GSH with a median 
follow-up of 23.0 (13.0 - 48.0) months. The patients were stratified according to treatment 
with baseline characteristics shown in Table 3.  
There was an equal distribution of black African patients between groups of patients treated 
and those not treated with ISP. Patients treated with ISP were older (46.3 ± 15.7 years vs 40.2 
± 15.7; p=0.20), had higher SBP (133.2 ± 3.9 mmHg vs 128.8 ± 3.6 mmHg; p=0.43) and had 
a higher proportion of prevalent hypertensives (43.8% vs 25.0%; p=0.19). Baseline eGFR 
was lower among the ISP-treated patients (89.3 ± 10.8 mls/min/1.73m2 vs. 113.0 ± 11.5 
mls/min/1.73m2, p=0.17); urinary protein excretion was higher in the ISP-treated group (1.12 
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± 0.11g/mmol). ISP-treated patients were more likely to present with nephrotic syndrome 
(93.8% vs 63.0%, p= 0.025) as they were also to present with a complication of nephrotic 
syndrome - mainly thromboembolic phenomena and infection. Angiotensin converting 
enzyme inhibitor (ACEi) therapy was instituted in at least 80% of patients in either treatment 
group (Table 3). 
Immunosuppressive therapy and outcomes  
All patients who received ISP received corticosteroids and cyclophosphamide. They were 
initiated on ISP after a period of conservative therapy with a median time to ISP initiation of 
6.0 (IQR 1.8-9.8) months. The mean cumulative dose of cyclophosphamide given was 5.5 ± 
2.9g. No patient got corticosteroid alone as initial therapy however 6 (14.0%) patients 
remained on low-dose oral corticosteroid at the last follow-up visit.  Fifty percent  (50.0%) of 
patients who received ISP therapy attained a partial or complete remission while 37.0% of 
patients who were conservatively managed attained either a partial or complete of remission, 
p=0.62 (Table 4).   
Trend of Proteinuria Response 
Figure 2 shows the proteinuria trend according to treatment category. Within ISP-treated 
patients there was a persistent decline in proteinuria at 12 months [-0.49 (CI -0.90 to -0.08) 
g/mmol, p=0.020) and 24 months (-0.62 (CI -1.10 to -0.13) g/mmol, p=0.013) from baseline. 
Similar significant trends were observed in the non-ISP group; there was therefore no 
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Time-to-Combined Remission Analysis 
The combined end-point of complete and partial remissions was analysed in the time-to-
remission analysis. The cumulative composite remission curve for the entire group is 
presented in Figure 3a. At 12- and 24-months respectively, 94.6% and 80.8% of all IMGN 
patients had not attained the combined end-point. Figure 3b shows the survival curves 
according to ISP status. ISP-treated patients had earlier remission rates, 13.3% in the first 12 
months in comparison to 0% remission events in the same period among the non-ISP treated 
group. At 24 months, 31.7% (CI: 12.9%-65.2%) of patients in the ISP group and 10.4% (CI: 
2.8%-37.3%) in the non-ISP group had attained the combined end-point. The median times-
to-remission of the groups were however similar at 48.6 (IQR 21.8-71.2) months and 48.7 
(IQR 33.3- 88.1) months, p=0.104 respectively (Figure 3b).  
Univariate Cox regression analysis showed that individuals in the ISP group were twice as 
likely to attain the composite end-point (HR 2.22, 95% CI =0.8 - 6.0, p=0.11). SBP was a 
predictor of composite remission at last visit (HR 0.97 [95% CI 0.95-0.99], p=0.039) and for 
every 10mmHg increase in SBP at last follow-up there was an associated 25% reduction in 
the hazard of the composite endpoint (HR 0.75 [95% CI 0.58-0.98]). Likewise eGFR at last 
visit was significantly associated with outcome (HR 1.01 [95% CI 1.001-1.023], p=0.041) 
with every 10mls/min increase in eGFR at last follow up increasing the hazard of the 
endpoint by 12% (HR 1.12 [95% CI 1.005-1.254]). Neither eGFR at the time of biopsy (HR 
1.00 [95%CI 0.99-1.01], p=0.73) nor systolic blood pressure at biopsy (HR 0.99 [95%CI 
0.96-1.02], p=0.73) was predictive of remission at last visit. Race, gender, IF at biopsy, EM- 
grade of IMGN and prevalent hypertension at biopsy were not significantly predictive of the 
hazards of combined remission at last follow up (Table 5). No multivariate Cox model 
significantly predicted combined remission.  
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Change in estimated glomerular filtration rate according to remission status 
The eGFR trend of subjects according to remission category at last follow-up visit is depicted 
in figure 3. There was a trend towards a significant difference in the eGFR profile over time 
between subjects with the composite outcome of complete and partial remission, and those 
who had not attained remission (p=0.06). In assessing eGFR trends within each group, there 
was no statistically significant decline in renal function relative to baseline eGFR at 6, 12 and 
24 months among those who achieved the composite outcome. In those who had not achieved 
any form of remission at the last follow up, eGFR decline relative to baseline was the most 
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DISCUSSION  
The overarching aim in the management of persistent proteinuric disorders is the prevention 
of renal function deterioration and progression to ESRD.16,17 Declining proteinuria in IMGN 
with the subsequent attainment of a complete or partial remission is known to correlate with 
better renal survival.14,18 The use of remission categories as endpoints in observational and 
experimental studies of IMGN is therefore commonly observed. In our retrospective review 
of the combined remission outcomes of either a complete or partial remission among patients 
managed with IMGN at GSH in Cape Town, we found poor remission rates at last follow-up 
visit of 41.9% among all patients, and 43.8% among patients with the nephrotic syndrome. 
Median time-to-remission was similar among actively and conservatively treated patients. 
Race, gender, and presence of IF at biopsy did not significantly influence time-to-remission. 
Both SBP and eGFR at last visit were predictive of remission. An evaluation of renal function 
over the duration of follow-up utilizing eGFR trends demonstrated a propensity towards 
stabilization of renal function among patients who attained any form of remission. 
Conversely, the most significant mean decline in eGFR of -18mls/min was observed at 12 
months of follow-up among subjects who had not attained any form of remission. To the best 
of our knowledge, this is the first remission outcome study of IMGN-only patients in Africa. 
In a 10-year follow-up review of patients who had been randomized to immunosuppressive 
treatment with steroids and an alkylating agent, Ponticelli and colleagues reported a 
combined remission rate of 48.1% rate which compares to the rate in our study.19 Troyanov et 
al in a Canadian cohort had achieved a 68% combined remission rate among IMGN patients 
with the nephrotic syndrome and in comparison, our remission rate of 43.8% is less 
favourable.14 Patients in both cohorts (Troyanov and ours) had mean ages within the 4th 
decade of life however 61% of their patients had been treated actively with at least one form 
of immunosuppression while only 46.9% had received active treatment in the Cape Town 
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group. The lower proportion of patients actively treated in our group may thus have 
accounted for this discrepancy. African ancestry has been established to be associated with a 
higher risk for kidney disease.20 Recently as well, APOL1 genetic susceptibilities have been 
shown to be associated with worse pathologic patterns in PLA2R1-associated IMGN in 
patients of African ancestry, and possibly play a role in clinical response.21 We propose that 
racial differences may thus be an additional and plausible reason for the differences we 
observe between this African cohort and other Caucasian cohorts. Indeed, it is known that 
Japanese patients with IMGN fare much better than their Caucasian counterparts.22  The 
added role of epigenetics in this variability needs further evaluation. 
Median time-to-composite remission in our study was prolonged at 48.6 months. Shorter 
times have been reported. In a 12-year review by McQuarrie et al, times to PR and CR were 
16.8 and 42.0 months respectively irrespective of treatment approach.23 Similarly, in Canada, 
times to PR and CR were 23 and 30 months respectively. These studies however consisted 
solely of patients with nephrotic syndrome. In contrast, 74.0% of our patients were nephrotic. 
Notably, our patients at baseline had a higher degree of proteinuria than any of the Western 
groups. This, in addition to our definition of partial remission, which requires an additional 
50% decline in the peak urinary protein value, would translate to longer transition times to 
remission. The clinical utility of proteinuria as an indicator of remission has been challenged 
by recent observations in anti-PLA2R antibodies-positive patients in whom remission of 
proteinuria lags behind the remission of anti-PLA2R antibodies by as much as 15 months.24 
We could not assess this phenomenon in our patients as the discovery of this antibody is a 
relatively recent discovery and there were no stored sera available for testing in our cohort.  
The use of immunosuppression did not significantly reduce the median time-to-remission 
which was 48.6 months among those immunosuppressed and 48.7 months in those 
conservatively managed in our study. This is similar to what has been described among larger 
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samples of Caucasian patients whereby ISP treatment did not significantly predict remission 
outcomes.14,23 In the setting of randomized clinical trials evaluating the role of ISP in 
inducing remission, highly significant differences have been shown based on treatment 
assignment. In the trial of Chlorambucil and Prednisone for IMGN, median time-to-remission 
was as short as 12 months in the actively treated arm with 5-year Kaplan-Meier remission 
estimates of 80%.  Such highly statistically significant remission estimates have however not 
been consistently demonstrated in observational studies, our study inclusive. The highly 
restrictive patient selection criteria into these RCTs (which do not usually typify patient 
populations in clinics) may also explain these discrepancies.  Our observation of non-
significant differences according to treatment status should also be regarded in the context of 
similar degrees of proteinuria at baseline between the ISP and non-ISP treated. The ISP 
regimen used in our patient cohort could also account for the lack of demonstrable treatment 
effect. Our cyclophosphamide-based protocol substitutes oral cyclophosphamide with IV 
cyclophosphamide in order to reduce the cumulative dose of administered drug. This 
substitution has been occasioned by the increased risk of infectious complications with 
cyclophosphamide in our setting. Among lupus-nephritis patients induced with oral 
cyclophosphamide at our centre, 37.5% of deaths were sepsis-related.25  
Protagonists for the use of ISP argue that beyond remission induction and renal function 
preservation, ISP use hastens the decline in proteinuria thus protecting IMGN patients from 
complications of the disease such as thromboembolic phenomena.26 Indeed in the course of 
follow-up 31.3% of IS-treated patients in our study developed a complication of nephrotic 
syndrome (Table 3).  
ESRD is a known consequence of IMGN and preventing its occurrence has been a major 
compelling indication for ISP treatment in IMGN. Although our study had a short follow-up 
time (relative to the natural history of IMGN) within which to evaluate renal survival with 
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certainty, we demonstrated a trend in renal function stabilization among patients who attained 
any form of remission irrespective of treatment category.  This trend is in agreement with the 
known relationship between remission status and renal prognosis.27 Troyanov and colleagues 
reported a 100%, 90%, and 45% 10-year renal survival respectively among patients who had 
attained complete, partial and no remission.14 In determining the factor(s) predictive of our 
demonstrated trend, eGFR at baseline was predictive in univariate analysis; baseline eGFR 
remained an independent predictor on multivariate analysis that had assessed additional 
predictors (supplementary Table 1). The short median duration of follow up could have 
accounted for the demonstrated lack of association between renal function and other known 
predictors (supplementary Table 1).  Renal function at baseline is a well-recognized predictor 
of renal outcome in IMGN so much so, it is one of the variables in the validated predictive 
risk scores of IMGN outcome. 28-30 
The retrospective design of the study and small sample size constrained this study’s power to 
influence change in current practice. It however generates a number of hypotheses which can 
be tested prospectively. These include the optimal ISP regimen for IMGN among African 
patients in relation to short term outcomes such as remission induction and the long term 
outcome of renal survival.  The relatively short duration of follow-up was also a limitation in 
assessing relapse among those who had attained remission, and also in describing ESRD 
outcomes. 
Remission outcomes with the current ISP treatment protocol for IMGN are delayed and poor. 
There is a need for its re-evaluation to assess the best treatment approach (-es) to IMGN in 
South Africa. 
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TABLES 
Table 1. Baseline demographic, clinical and biochemical features of all idiopathic 
membranous glomerulonephritis patients 
Baseline Characteristic Patients, N=56 
Age (years) 41.5 ± 14.6 
Female n (%) 26 (46.4%) 
Black n (%) 21 (37.5%) 
SBP (mmHg) 130.1 ± 18.2 
DBP (mmHg) 79.7 ± 11.5 
Creatinine at diagnosis (µmol/L) 79.5 (IQR: 61.6 - 118.0) 
eGFR   (mls/min) 88.6 (IQR: 60.0 - 134.8) 
Median uPCR (g/mmol) 9.8 (6.6-13.7) 
Mean Albumin (g/L) 19.1 ± 7.0 
Mean Cholesterol (mmols/L) 10.0 (7.3, 12.4) 
Nephrotic syndrome n (%) 43 (76.7) 
SBP- systolic blood pressure, DBP- diastolic blood pressure, eGFR-estimated glomerular filtration rate, IQR- interquartile range, uPCR-spot 
urine-to-creatinine ratio. 
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Table 2. Histologic findings of all patients at the time of biopsy 
 
CHARACTERISTICS VALUE 
Number of glomeruli   mean, SD 12.7  ± 7.8 
Sclerosed glomeruli median (min, max) 0 (0,3) 
EM grading n/N (%)  
Grade 1 6/47 (12.8)  
Grade 2  16/47 (34.0) 
Grade 3  10/47 (21.3) 
Grade 4 15/47 (31.9) 
Interstitial fibrosis n/N (%)  
Normal  29/51 (56.9) 
Mild 18/51 (35.3) 
Moderate  2/51 (3.9) 
Severe 2/51 (3.9) 
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Age (years) 46.3 ± 13.7 40.2  ± 15.7 0.20 
Female n (%) 7 (43.8%) 13 (48.2%) 0.52 
Black n (%)  5 (31.3%) 9 (33.3%) 0.88 
SBP (mmHg) 133.2  ± 3.9 128.8  ± 3.6 0.43 
DBP (mmHg)  77.7  ± 3.0 81.0  ± 2.1 0.37 
Hypertension n (%) 7 (43.8%) 6 (25.0%) 0.19 
sCreatinine (µmol/L) 123.4 ± 35.7 83.5 ± 7.6 0.23 
eGFR (mls/min) 89.3  ± 10.8 113.0  ± 11.5 0.17 
sAlbumin (g/L) 20.1 ± 1.1 19.8 ± 1.7 0.89 
UPCR (g/mmol) 1.12 ± 0.11  1.06 ± 0.16 0.75 
ACEi n (%) 13 (81.3%) 22 (95.7%) 0.15 
Statins n (%) 14 (87.5%) 18 (66.7%) 0.64 
Nephrotic syndrome n (%) 15 (93.8) 17 (63.0) 0.025* 
Complications of nephrotic 
syndrome n (%) 
5 (31.3%) 2 (7.4%) 0.021*# 
* P< 0.05, SBP- systolic blood pressure  DBP- diastolic blood pressure, eGFR-estimated glomerular filtration rate, uPCR-spot urine-to-
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Remission status n (%)    
P= 0.62 
Complete 2 (12.5%) 4 (14.8%) 
Partial 6 (37.5%) 6 (22.2%) 
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Table 5. Univariate Cox regression analysis for selected predictors of the endpoint of 
any remission 
 
Variable HR 95%  CI P Value 
Age  1.01 0.97- 1.04 0.61 
Race (Black) 1.04 0.38 – 2.84 0.93 
Gender (Male) 1.46 0.54 – 3.96 0.45 
Interstitial fibrosis (Present) 1.59 0.50 – 4.48 0.38 
eGFR at biopsy 1.00 0.99 - 1.01 0.73 
SBP at biopsy 0.99 0.96 - 1.02 0.59 
DBP at biopsy 0.99 0.94 - 1.05 0.74 
eGFR last follow-up 1.01 1.001 - 1.02 0.041 
SBP at last follow-up 0.97 0.94 - 0.99 0.036 
DBP at last follow-up 0.98 0.95 - 1.01 0.24 
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6Supplementary Table 1. Multivariate model of trend in estimated glomerular filtration  
 
 

































 Coefficient 95% CI p Value 
eGFR at biopsy 0.89 0.77-1.007 0.001 
Race (black) 4.54 -7.11 – 16.19 0.45 
Gender (Female) 10.07 -0.63 -20.76 0.07 
Interstitial fibrosis 1.19 -11.03-3.41 0.85 
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LEGENDS TO FIGURES 
Figure 1.  Patient selection flow-chart 
Figure 2. Proteinuria response profile according to immunosuppression status 
Figure 3. Kaplan-Meier curves for time to any remission 
(a) Entire group
(b) By immunosuppression   use
Figure 4. Estimated glomerular filtration rate profile by remission status 
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Idiopathic MGN treated and 
followed up at DNH-GSH
N=43
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Figure 2. Proteinuria response profile according to immunosuppression status 
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Figure 3.  Kaplan-Meier curves for time to any remission 
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Figure 4. Estimated glomerular filtration rate profile by remission status 
CR-complete remission; PR; Partial remission 
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Appendix 1: Nephrology Dialysis Transplantation (NDT) -Basic and Clinical Sciences 
Journal Instruction to Authors of Original Articles  
Aims and Scope of the Journal 
NDT – Basic and Clinical Science is an official publication of the European Renal Association-
European Dialysis and Transplant Association. NDT publishes Editorials, Reviews and original 
research. The journal covers the whole territory of nephrology research including experimental work 
in animal models and molecular biology studies. In the Clinical Science section we consider clinical 
trials (RCT have a priority in our journal), observational studies at large and original works on health 
economy as applied to nephrology. We aim to cover the whole spectrum of kidney disease research, 
from clinical nephrology to haemodialysis and peritoneal dialysis as well as renal transplantation. 
Authors’ role and responsibility 
Each author should have participated sufficiently in the work to take public responsibility for the 
content.  
Manuscripts should bear the full name and address, with telephone, fax, and email of the author to 
whom the proofs and correspondence should be sent (corresponding author). For all authors, first 
name and surname should be written in full.  
In a covering letter, the individual contribution of each co-author must be detailed. This letter must 
contain the statement: 'the results presented in this paper have not been published previously in 
whole or part, except in abstract form'. Should your manuscript be accepted for publication, you will 
be required to give signed consent for publication 
Preparation of the Manuscript to be submitted in NDT 
Word count: maximum 3500 words, including abstract but excluding references, tables and figures. 
Keywords: maximum 6 
References: maximum 60 
The order of original articles should be as follows: 
1. Title page including the title (please bear in mind that we prefer a title to be concise yet eye-
catching) and details of all authors, including first or given name, and affiliation;
2. On a separate page an abstract of ~250 words. It should consist of four paragraphs labelled
`Background', `Methods', `Results' and `Conclusions'. They should briefly describe, respectively, the
problems being addressed in this study, how the study was performed, the salient results and what
the authors conclude from the results.
3. Keywords: no more than 6, in alphabetical order, characterizing the scope of the paper, the
principal materials, and main subject of work.
4. Provide a short summary of max 3-4 sentences pointing out the main message of the paper.
5. On a new page: Introduction, Subjects and Methods, Results, Discussion, Acknowledgements,
References, Tables, Legends to figures and Figures. All pages should be numbered consecutively
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commencing with the title page. Headings (Introduction; Subjects and Methods, etc) should be 
placed on separate lines. It is important that authors number their pages prior to submission as 
reviewers will refer to particular pages when providing their comments on the manuscript. 
Any statistical method must be detailed in the Subjects and Methods section, and any not in 
common use should be described fully or supported by references. 
Abbreviations 
Authors should not use abbreviations in headings and figure legends should be comprehensive 
without extensive repetition of the Subjects and Methods section. Authors are advised to refrain 
from excessive use of uncommon abbreviations, particularly to describe groups of patients or 
experimental animals. 
References 
The references should be numbered in the order in which they appear in the text. References to 
published abstracts should be mentioned in the text but not in the reference list. 
At the end of the article the full list of references should give the name and initials of all authors 
unless there are more than six, when only the first three should be given followed by et al. The 
authors' names should be followed by the title of the article, the title of the Journal abbreviated 
according to the style of Index Medicus, the year of publication, the volume number and the first 
and last page numbers. References to books should give the title of the book, which should be 
followed by the place of publication, the publisher, the year and the relevant pages. 
EXAMPLES 
1. Madaio MP. Renal biopsy. Kidney Int 1990; 38: 529-543
Books: 
2. Roberts NK. The cardiac conducting system and the His bundle electrogram. Appleton-Century-
Crofts, New York, NY: 1981; 49-56
Chapters: 
3. Rycroft RJG, Calnan CD. Facial rashes among visual display unit (VDU) operators. In: Pearce BG, ed.
Health hazards of VDUs. Wiley, London, UK: 1984; 13-15
Note: In the online version of NDT, there are automatic links from the reference section of each 
article to Medline. This is a useful feature for readers, but is only possible if the references are 
accurate. It is the responsibility of the author to ensure the accuracy of the references in the 
submitted article. Downloading references direct from Medline is highly recommended. 
Tables and Figures Preparation 
All tables must be numbered consecutively and each must have a brief heading describing its 
contents. Any footnotes to tables should be indicated by superscript characters. Tables must be 
referred to in the main text in running order. All tables must be simple and not duplicate information 
given in the text. 
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Please be aware that the requirements for online submission and peer review, please upload your 
figures either embedded in the word processing file or separately as low-resolution images (.jpg, .tif, 
.gif or. eps). 
Supplementary Material 
Supporting material that is not essential for inclusion in the full text of the manuscript, but would 
nevertheless benefit the reader, can be made available by the publisher as online-only content, 
linked to the online manuscript. Such material should not be essential to understanding the 
conclusions of the paper, but should contain data that is additional or complementary and directly 
relevant to the article content. Such information might include more detailed methods, extended 
data sets/data analysis, or additional figures (including colour). 
All material to be considered as Supplementary material must be submitted at the same time as the 
main manuscript for peer review. It cannot be altered or replaced after the paper has been accepted 
for publication. Please indicate clearly the material intended as Supplementary material upon 
submission. Also ensure that the Supplementary material is referred to in the main manuscript 
where necessary. 
Transparency Declaration and Ethics 
All authors must make a formal declaration at the time of submission indicating any potential 
conflict of interest. This is a condition of publication and failure to do so will delay the review 
process. Such declarations might include, but are not limited to, shareholding in or receipt of a grant, 
travel award or consultancy fee from a company whose product features in the submitted 
manuscript or a company that manufactures a competing product. 
In addition, in the interests of openness, ALL papers submitted to NDT MUST include a ‘Transparency 
declarations’ section (which should appear at the end of the paper, before the ‘References’ section) 
within the article. We suggest authors concentrate on transparency declarations (i.e. conflicts of 
interest) of a financial nature, although relevant non-financial disclosures can also be made. 
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Appendix 2: Ethics Approval Letter  
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